Trial Profile
A Phase 3, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Evaluate The Safety And Tolerability Of Dimebon (PF-01913539) For Up To 26-Weeks In Patients With Mild To Moderate Alzheimer's Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Registrational
- 04 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Jun 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov (NCT00939783).